Kodiak Sciences Inc (KOD)
3.29
-0.45
(-12.03%)
USD |
NASDAQ |
May 17, 16:00
3.29
0.00 (0.00%)
After-Hours: 20:00
Kodiak Sciences Cash from Operations (TTM): -146.56M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -146.56M |
December 31, 2023 | -154.18M |
September 30, 2023 | -177.02M |
June 30, 2023 | -197.34M |
March 31, 2023 | -210.52M |
December 31, 2022 | -206.46M |
September 30, 2022 | -210.42M |
June 30, 2022 | -209.28M |
March 31, 2022 | -190.80M |
December 31, 2021 | -182.27M |
September 30, 2021 | -150.25M |
Date | Value |
---|---|
June 30, 2021 | -122.88M |
March 31, 2021 | -100.12M |
December 31, 2020 | -83.43M |
September 30, 2020 | -67.70M |
June 30, 2020 | -50.83M |
March 31, 2020 | -49.87M |
December 31, 2019 | -39.15M |
September 30, 2019 | -36.19M |
June 30, 2019 | -33.48M |
March 31, 2019 | -24.98M |
December 31, 2018 | -29.03M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-210.52M
Minimum
Mar 2023
-33.48M
Maximum
Jun 2019
-130.94M
Average
-148.41M
Median
Cash from Operations (TTM) Benchmarks
Avalo Therapeutics Inc | -26.83M |
Regeneron Pharmaceuticals Inc | 4.739B |
Ligand Pharmaceuticals Inc | 34.36M |
iBio Inc | -18.89M |
Dare Bioscience Inc | -29.55M |